Iconovo is a Swedish inhalation platform company developing complete inhalation products, combining proprietary dry powder inhaler devices with formulation expertise. The company enables pharmaceutical partners to efficiently develop and commercialize both generic and novel inhaled therapies.
Iconovo has built a portfolio of proprietary inhalation platforms, including ICOres® (Turbuhaler-compatible), ICOpre® (Ellipta-compatible), and ICOcap® (capsule-based platforms comparable to Breezhaler and HandiHaler), as well as ICOone® and ICOone Nasal® for single-use and intranasal delivery. By delivering substitutable integrated drug–device combinations, Iconovo supports partners in accelerating time to market through out-licensing and collaborative development models.
